 |
|
|
|
|
|
 Title: |
US5189020:
Method of reducing neuronal damage using omega conotoxin peptides
[ Derwent Title ]
|
| Country: |
US United States of America
|
| |
| Inventor: |
Miljanich, George P.; Redwood City, CA
Bitner, Robert S.; Mountain View, CA
Bowersox, Stephen S.; Menlo Park, CA
Fox, James A.; Palo Alto, CA
Valentino, Karen L.; San Carlos, CA
Yamashiro, Donald H.; San Francisco, CA
Tsubokawa, Makoto; South San Francisco, CA
|
| Assignee: |
Neurex Corporation, Menlo Park, CA
other patents from NEUREX CORPORATION (397535) (approx. 15)
News, Profiles, Stocks and More about this company
|
| Published / Filed: |
1993-02-23
/ 1990-08-02
|
| Application Number: |
US1990000561766
|
| IPC Code: |
Advanced:
C07K 14/435;
A61K 38/00;
Core:
more...
IPC-7:
A61K 37/02;
C07K 7/06;
C07K 7/08;
C07K 7/10;
|
| U.S. Class: |
Current:
514/012;
514/013;
514/014;
514/015;
514/021;
530/324;
530/325;
530/326;
530/327;
Original:
514/012;
514/013;
514/014;
514/015;
514/021;
530/324;
530/325;
530/326;
530/327;
|
| Field of Search: |
514/012,21,13,14,15
530/324,325,326,327
|
| Priority Number: |
|
| Abstract: |
A partially purified omega conotoxin binding protein is disclosed. The protein, either in partially purified form or in a synaptosomal preparation, is useful in identifying compounds for use in reducing neuronal damage related to an ischemic condition, such as stroke, in a human patient.
|
| Attorney, Agent or Firm: |
Dehlinger, Peter J. ;
|
| Primary / Asst. Examiners: |
Cashion, Jr., Merrell C.; Rozycki, Andrew G.
|
| INPADOC Legal Status: |
Show legal status actions
Family Legal Status Report
|
|
|
|
|
|
|
| Parent Case: |
This application is a continuation-in-part of U.S. Pat. application for "Method of Treating Ischemia-Related Neuronal Damage," Ser. No. 440,094, filed Nov. 22, 1989, now U.S. Pat. No. 5,051,403.
|
| Designated Country: |
AU CA EP HU JP KR NO SU
|
| Family: |
Show 23 known family members
|
First Claim:
Show all 4 claims |
It is claimed:
1. A method of reducing neuronal damage related to an ischemic condition affecting the central nervous system in a mammalian subject, comprising:
- administering to the subject in a pharmaceutically effective amount, an omega conotoxin (OCT) peptide, including a fragment thereof, effective (i) to bind to an omega conotoxin binding protein, with a binding constant which is within the range of binding affinities of MVIIA, MVIIB, GVIA, GVIIA and RVIA omega conotoxins, (ii) to inhibit voltage-gated calcium currents selectively in neuronal tissue with an ED50 value which is within the range of ED50 values of MVIIA, MVIIB, GVIA, GVIIA and RVIA omega conotoxins, and (iii) to inhibit neurotransmitter release selectively in neuronal tissue, with an IC50 which is within the range of MVIIA, MVIIB, GVIA, GVIIA and RVIA omega conotoxins.
|
| Background / Summary: |
Show background / summary
|
| Drawing Descriptions: |
Show drawing descriptions
|
| Description: |
Show description
|
| Forward References: |
Show 29 U.S. patent(s) that reference this one
|
|
|
|
|
|
|
| Foreign References: |
None
|
| Other Abstract Info: |
CHEMABS 115(25)270696K
DERABS C91-192969
|
| Other References: |
Hamilton et al., Report 1989-Govt. Rep. Announce. Index (US), vol. 89 (22) p. 173 entry #960328 (1989).
Govoni et al., Minerva Med. vol. 77 (24) pp. 1053-1058 (1986) (abstract).
Iida et al., Jpn. Heart 3, vol. 31 (4) p. 536 (1990).
Mossakowski et al. Neuropat. Pol., vol. 25 (4) pp. 439-450 (1987).
Shapira et al., Brain Res., vol. 523 (2) pp. 291-294 (1990).
(4 pages)
Choi, D. W., "Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage" TINS, vol. 11 (10) pp. 465-469 (1988).
(5 pages)
Cited by 10 patents
Bean, B. P., Annu. Rev. Physiol. 51:367-384 (1989).
(18 pages)
Cited by 37 patents
Greenberg, D. A., Curr. Neurol. 6:91-121 (1986).
Hossmann, K.-A, "Calcium antagonists for the treatment of brain ischemia: A critical appraisal".
Marqueze, Beatrice, et al., Molecular Pharmacology, 34:87-90 (1988).
(4 pages)
Cited by 3 patents
Vibulsreth, S., et al., Stroke 18:210-216 (1987).
(7 pages)
Ahmad, S., et al., Brain Research, 453:247-256 (1988).
(10 pages)
Cited by 3 patents
Anderson, A. J., et al., Neuroscience Letts., 82:177-180 (1987).
(4 pages)
Cited by 2 patents
Bennett, J. P. et al., Neutransmitter Receptor Binding, pp. 61-89 Raven Press, NY (1983).
Gray, W. R., et al., Ann. Rev. Biochem., 57, pp. 655-700 (1988).
Haley, T., et al., Brit. J. Pharmacol., 23, pp. 12-15 (1957).
Kirino, T., Brain Research, 239, pp. 57-69 (1982).
(13 pages)
Cited by 8 patents
McCleskey, E. W., et al., PNAS, 84, pp. 4327-4331 (1987).
Olivera, B., et al., Science, 230, pp. 1338-1343 (1985).
(6 pages)
Cited by 25 patents
Pulsinelli, W. A., et al., Stroke, 10, pp. 267-272 (1979).
(6 pages)
Cited by 6 patents
Sano, K., et al., Eur. J. Pharmacol., 141, pp. 235-141 (1987).
(7 pages)
Cited by 3 patents
Tsien, R. W., et al., TINS, 11, pp. 431-438 (1988).
Van Reempts, J., et al., Acad. Anaesthesiolica Belge, 35, Suppl., pp. 209-218 (1984).
Wauquier, A., et al., Neuroscience and Biobehaviorial Reviews, 11, pp. 287-306 (1987).
(20 pages)
Cited by 3 patents
Yamaguchi, T., Klatzo, I., in Cerebral ishemia, (Bes, A., Braquet, P., and Sisejo, B. K., eds.), Elsevier Sciences Publ., pp. 13-24 (1984).
Yamashiro, D., Int. J. Protein Peptide Res., 30, pp. 9-12 (1987).
(4 pages)
Cited by 2 patents
Alps, B. J., et al., Neurology, 37, pp. 809-815 (1987).
(6 pages)
Cruz, L. J., et al., Biochemistry, 26, pp. 820-824 (1987).
(5 pages)
Cited by 13 patents
Grotta, J. C., et al., Ann. Neurol., 27, pp. 612-619 (1990).
(8 pages)
Jones, O. T., et al., Science, 244, pp. 1189-1193 (1989).
(5 pages)
Cited by 4 patents
Olivera, B. M., et al., Biochemistry, 26, pp. 2086-2090 (1987).
(5 pages)
Cited by 19 patents
Simon, R. P., et al., Science, 226, pp. 850-852 (1984).
(3 pages)
Cited by 29 patents
Onodera, H., et al., Stroke, 21, pp. 771-776 (1990).
(6 pages)
|
|
 Nominate this for the Gallery...
|
|
